SE9903544D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE9903544D0
SE9903544D0 SE9903544A SE9903544A SE9903544D0 SE 9903544 D0 SE9903544 D0 SE 9903544D0 SE 9903544 A SE9903544 A SE 9903544A SE 9903544 A SE9903544 A SE 9903544A SE 9903544 D0 SE9903544 D0 SE 9903544D0
Authority
SE
Sweden
Prior art keywords
novel compounds
solvate
chem
therapy
processes
Prior art date
Application number
SE9903544A
Other languages
English (en)
Swedish (sv)
Inventor
Roger Bonnert
Fraser Hunt
Paul Willis
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Priority to SE9903544A priority Critical patent/SE9903544D0/xx
Publication of SE9903544D0 publication Critical patent/SE9903544D0/xx
Priority to CZ20021113A priority patent/CZ20021113A3/cs
Priority to DE60007768T priority patent/DE60007768T2/de
Priority to DE60037836T priority patent/DE60037836T2/de
Priority to EP03015019A priority patent/EP1348709B1/en
Priority to EP00960891A priority patent/EP1222195B1/en
Priority to PT00960891T priority patent/PT1222195E/pt
Priority to PCT/GB2000/003692 priority patent/WO2001025242A1/en
Priority to ES00960891T priority patent/ES2213043T3/es
Priority to IL14891000A priority patent/IL148910A0/xx
Priority to SI200030314T priority patent/SI1222195T1/xx
Priority to EEP200200174A priority patent/EE05037B1/xx
Priority to DK00960891T priority patent/DK1222195T3/da
Priority to PL365778A priority patent/PL203572B1/pl
Priority to JP2001528186A priority patent/JP4824889B2/ja
Priority to KR1020027004180A priority patent/KR100765051B1/ko
Priority to AT03015019T priority patent/ATE384068T1/de
Priority to NZ517880A priority patent/NZ517880A/en
Priority to UA2002032035A priority patent/UA73521C2/uk
Priority to CNB008163189A priority patent/CN1210279C/zh
Priority to CA2385269A priority patent/CA2385269C/en
Priority to AU73049/00A priority patent/AU777872B2/en
Priority to US10/089,571 priority patent/US6790850B1/en
Priority to AT00960891T priority patent/ATE257838T1/de
Priority to ES03015019T priority patent/ES2298451T3/es
Priority to HU0204246A priority patent/HUP0204246A3/hu
Priority to MXPA02003263A priority patent/MXPA02003263A/es
Priority to BR0014334-0A priority patent/BR0014334A/pt
Priority to TW089121952A priority patent/TWI260324B/zh
Priority to IS6306A priority patent/IS2229B/is
Priority to NO20021448A priority patent/NO327706B1/no
Priority to ZA200202380A priority patent/ZA200202380B/en
Priority to IL148910A priority patent/IL148910A/en
Priority to HK03104330A priority patent/HK1052009A1/xx
Priority to US10/863,995 priority patent/US20040224961A1/en
Priority to US12/432,224 priority patent/US8143261B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE9903544A 1999-10-01 1999-10-01 Novel compounds SE9903544D0 (sv)

Priority Applications (36)

Application Number Priority Date Filing Date Title
SE9903544A SE9903544D0 (sv) 1999-10-01 1999-10-01 Novel compounds
NZ517880A NZ517880A (en) 1999-10-01 2000-09-26 Novel thiazolo(4,5-D)pyrimidine compounds
AT03015019T ATE384068T1 (de) 1999-10-01 2000-09-26 Thiazolo(4,5-d)pyrimidinverbindungen zur behandlung von rheumathoider arthritis
UA2002032035A UA73521C2 (en) 1999-10-01 2000-09-26 Thiazolo[4,5-d]pyrimidine derivatives, a method for the preparation thereof (variants), intermediary compounds, pharmaceutical composition based thereon and a method for the preparation of such composition
DE60037836T DE60037836T2 (de) 1999-10-01 2000-09-26 ThiazoloÄ4,5-dÜpyrimidinverbindungen zur Behandlung von rheumathoider Arthritis
DE60007768T DE60007768T2 (de) 1999-10-01 2000-09-26 Neue thiazolo(4,5-d)pyrimidinverbindungen
EP00960891A EP1222195B1 (en) 1999-10-01 2000-09-26 Novel thiazolo(4,5-d)pyrimidine compounds
CNB008163189A CN1210279C (zh) 1999-10-01 2000-09-26 新的噻唑并(4,5－d)嘧啶化合物
PCT/GB2000/003692 WO2001025242A1 (en) 1999-10-01 2000-09-26 Novel thiazolo(4,5-d)pyrimidine compounds
ES00960891T ES2213043T3 (es) 1999-10-01 2000-09-26 Nuevos compuestos de tiazolo(4,5-d)pirimidina.
IL14891000A IL148910A0 (en) 1999-10-01 2000-09-26 Novel thiazolo (4,5-d) pyrimidine compounds
SI200030314T SI1222195T1 (en) 1999-10-01 2000-09-26 Novel thiazolo(4,5-d)pyrimidine compounds
EEP200200174A EE05037B1 (et) 1999-10-01 2000-09-26 Tiasolo( 4,5-d) primidiinihendid, meetod nende valmistamiseks ning neid sisaldav ravimkoostis
DK00960891T DK1222195T3 (da) 1999-10-01 2000-09-26 Hidtil ukendte thiazolo[4,5-d]pyrimidinforbindelser
PL365778A PL203572B1 (pl) 1999-10-01 2000-09-26 Zwi azek tiazolo[4,5-d]pirymidynowy, sposób jego wytwarzania, zwi azki po srednie, srodek farmaceutyczny oraz zastosowanie tego zwi azku
JP2001528186A JP4824889B2 (ja) 1999-10-01 2000-09-26 新規チアゾロ（４，５−ｄ）ピリミジン化合物
KR1020027004180A KR100765051B1 (ko) 1999-10-01 2000-09-26 신규 티아졸로(4,5-ｄ)피리미딘 화합물
CZ20021113A CZ20021113A3 (cs) 1999-10-01 2000-09-26 Deriváty thiazolo [4,5-d]pyrimidinu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
BR0014334-0A BR0014334A (pt) 1999-10-01 2000-09-26 Novos compostos de tiazolo (4,5-d) pirimidina
EP03015019A EP1348709B1 (en) 1999-10-01 2000-09-26 Thiazolo[4,5-d]pyrimidine compounds for the treatment of rheumatoid arthritis
PT00960891T PT1222195E (pt) 1999-10-01 2000-09-26 Novos compostos de tiazolo(4,5-d)pirimidina
CA2385269A CA2385269C (en) 1999-10-01 2000-09-26 Novel thiazolo(4,5-d)pyrimidine compounds
AU73049/00A AU777872B2 (en) 1999-10-01 2000-09-26 Novel thiazolo(4,5-D)pyrimidine compounds
US10/089,571 US6790850B1 (en) 1999-10-01 2000-09-26 Thiazolo(4,5-d)pyrimidine compounds
AT00960891T ATE257838T1 (de) 1999-10-01 2000-09-26 Neue thiazolo(4,5-d)pyrimidinverbindungen
ES03015019T ES2298451T3 (es) 1999-10-01 2000-09-26 Compuestos de tiazolo (4,5-d)pirimidina para el tratamiento de la artritis reumatoide.
HU0204246A HUP0204246A3 (en) 1999-10-01 2000-09-26 Novel thiazolo[4,5-d]pyrimidine compounds, process for their preparation, pharmaceutical compositions containing them and their use
MXPA02003263A MXPA02003263A (es) 1999-10-01 2000-09-26 Compuestos novedosos de tiazol(4,5-d)pirimidina.
TW089121952A TWI260324B (en) 1999-10-01 2000-10-19 Thiazolopyrimidinone compounds, process for preparing the same, and pharmaceutical composition comprising the same
IS6306A IS2229B (is) 1999-10-01 2002-03-18 Ný þíasóló(4,5-d)pýrimídínefnasambönd
NO20021448A NO327706B1 (no) 1999-10-01 2002-03-22 Nye tiazolo-(4,5-D)pyrimidinforbindelser, fremgangsmate for fremstilling derav, farmasoytisk preparat og mellomprodukter
ZA200202380A ZA200202380B (en) 1999-10-01 2002-03-25 Novel thiazolo(4,5-D)pyrimidine compounds.
IL148910A IL148910A (en) 1999-10-01 2002-03-26 7 - Amino - Thiazole (D – 5,4) Pyrimidine - 2 - (N3) - Converted lobes in position 5, their preparation, pharmaceutical preparations containing them and a number of their intermediates
HK03104330A HK1052009A1 (en) 1999-10-01 2003-06-17 Novel thiazolo (4,5-D) pyrimidine compounds
US10/863,995 US20040224961A1 (en) 1999-10-01 2004-06-09 Novel thiazolo (4,5-D) pyrimidine compounds
US12/432,224 US8143261B2 (en) 1999-10-01 2009-04-29 Thiazolo (4,5-D) pyrimidine compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903544A SE9903544D0 (sv) 1999-10-01 1999-10-01 Novel compounds

Publications (1)

Publication Number Publication Date
SE9903544D0 true SE9903544D0 (sv) 1999-10-01

Family

ID=20417218

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9903544A SE9903544D0 (sv) 1999-10-01 1999-10-01 Novel compounds

Country Status (27)

Country Link
US (3) US6790850B1 (uk)
EP (2) EP1348709B1 (uk)
JP (1) JP4824889B2 (uk)
KR (1) KR100765051B1 (uk)
CN (1) CN1210279C (uk)
AT (2) ATE384068T1 (uk)
AU (1) AU777872B2 (uk)
BR (1) BR0014334A (uk)
CA (1) CA2385269C (uk)
CZ (1) CZ20021113A3 (uk)
DE (2) DE60007768T2 (uk)
DK (1) DK1222195T3 (uk)
EE (1) EE05037B1 (uk)
ES (2) ES2298451T3 (uk)
HK (1) HK1052009A1 (uk)
HU (1) HUP0204246A3 (uk)
IL (2) IL148910A0 (uk)
IS (1) IS2229B (uk)
MX (1) MXPA02003263A (uk)
NO (1) NO327706B1 (uk)
NZ (1) NZ517880A (uk)
PT (1) PT1222195E (uk)
SE (1) SE9903544D0 (uk)
TW (1) TWI260324B (uk)
UA (1) UA73521C2 (uk)
WO (1) WO2001025242A1 (uk)
ZA (1) ZA200202380B (uk)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
JP2003522191A (ja) * 2000-02-11 2003-07-22 アストラゼネカ・アクチエボラーグ ケモカイン受容体活性のモジュレーターとしてのピリミジン化合物およびそれらの使用
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
SE0101322D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
ATE447577T1 (de) 2001-12-06 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer
US7262186B2 (en) 2001-12-06 2007-08-28 Merck & Co., Inc. Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor
GB0217431D0 (en) * 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
ATE323702T1 (de) 2002-08-06 2006-05-15 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
ES2295685T3 (es) 2002-08-24 2008-04-16 Astrazeneca Ab Derivados de pirimidina como moduladores de la actividad del receptor de quimioquinas.
GB0221828D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
JP2007507494A (ja) * 2003-10-07 2007-03-29 アストラゼネカ・アクチエボラーグ ケモカイン受容体アンタゴニストとりわけＣＸ３ＣＲ１として有用な新規な２−置換４−アミノ−チアゾロ［４，５−ｄ］ピリミジン
GB0328243D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Methods
CN102796081B (zh) 2004-08-28 2015-04-22 阿斯利康(瑞典)有限公司 作为趋化因子受体调节剂的嘧啶磺酰胺衍生物
US20090239882A1 (en) * 2004-12-17 2009-09-24 Astrazeneca Ab Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity
WO2006101439A1 (en) * 2005-03-23 2006-09-28 Astrazeneca Ab Screen
UA90707C2 (en) * 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es) * 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
AR071036A1 (es) * 2008-03-26 2010-05-19 Astrazeneca Ab Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1.
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
CN101899058B (zh) * 2010-05-24 2012-05-23 中国人民解放军第四军医大学 一种噻唑并嘧啶化合物及其制备方法和应用
DK3441474T3 (da) 2013-06-18 2020-08-17 Univ New York Farmaceutiske sammensætninger indeholdende et muteret leukocidin e
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
CN105683202B (zh) * 2013-08-02 2019-05-10 Syntrix生物系统公司 一种硼酸化合物
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
CN110172067B (zh) * 2019-04-11 2021-06-15 河南科技大学第一附属医院 一种具有杀菌活性的噻唑类药物分子及其制备方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2924472A (en) * 1957-06-27 1960-02-09 Gen Motors Corp Pipe joint seal
GB1009477A (en) 1962-02-13 1965-11-10 Smith Kline French Lab Novel process for preparing heterocyclic compounds
US3182062A (en) * 1962-02-28 1965-05-04 Smith Kline French Lab Synthesis of quinoxalines and analogues thereof
US3318900A (en) * 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
BE668603A (uk) * 1964-08-20
DE2331223C2 (de) 1972-06-19 1984-11-22 Kohjin Co., Ltd., Tokio / Tokyo S-substituierte-2-Thioadenosine, deren 5'-Monophosphate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten
US4120521A (en) * 1975-08-28 1978-10-17 Rieber & Son Plastic-Industri A/S Combined mould element and sealing ring
EG12406A (en) * 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
GB1600293A (en) * 1977-02-04 1981-10-14 British Oceanics Ltd Sealing arrangements
US4188040A (en) * 1977-04-06 1980-02-12 Firma WOCO Franz-Josef Wolf & Co. Sealing ring
DE2726959A1 (de) * 1977-06-15 1979-01-18 Arlt Christian Dichteinsatz zum dichten verbinden von zwei rohren
FR2421899A1 (fr) * 1978-01-16 1979-11-02 Roussel Uclaf Nouveaux derives du tetrahydropyridinyl-indole et leurs sels, le procede de preparation et l'application a titre de medicaments de ces nouveaux produits
US4410528A (en) * 1980-05-16 1983-10-18 Kyowa Hakko Kogyo Co., Ltd. Hypotensive piperidine derivatives
DE3219522A1 (de) * 1981-10-28 1983-12-01 Denso-Chemie Wedekind Kg, 5090 Leverkusen Steckmuffendichtung fuer rohre
FR2547888B1 (fr) * 1983-06-22 1985-12-13 Sabla Sa Bague d'etancheite a implants pour tuyaux a emboitement
CA1338012C (en) 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
SE8800348L (sv) * 1988-02-03 1989-08-04 Forsheda Ab Taetningsring och verktyg foer framstaellning daerav
FR2659656B1 (fr) 1990-03-15 1994-09-09 Sanofi Sa Derives de pyrimidinedione-2,4 et medicaments les contenant.
DE4119767A1 (de) * 1991-06-15 1992-12-17 Dresden Arzneimittel Verfahren zur herstellung von (pyrimid-2-yl-thio- bzw. seleno)-essigsaeurederivaten
US5169161A (en) * 1991-09-19 1992-12-08 Hail Mary Rubber Co., Inc. Symmetrical gasket for pipe joints
DE4134089C2 (de) * 1991-10-15 1994-10-13 Dueker Eisenwerk Schubgesicherte Muffenverbindung
JPH05188994A (ja) 1992-01-07 1993-07-30 Sony Corp 騒音抑圧装置
DE4229609C2 (de) * 1992-09-04 2003-05-08 Forsheda Stefa Gmbh Abdichtung zwischen zwei ineinandersteckbaren Teilen
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
EP0778277B1 (en) * 1995-12-08 2003-06-25 Pfizer Inc. Substituted heterocyclic derivatives as CRF antagonists
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
SE515033C2 (sv) * 1995-12-27 2001-06-05 Forsheda Ab Tätningsanordning
EP0880508B1 (en) 1996-02-13 2003-04-16 AstraZeneca AB Quinazoline derivatives as vegf inhibitors
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
WO1997040035A1 (en) 1996-04-19 1997-10-30 Neurosearch A/S 1-(4-piperidyl)-benzimidazoles having neurotrophic activity
EP0923582B1 (en) * 1996-08-28 2006-09-20 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
WO1998025617A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
AU8576098A (en) 1997-07-25 1999-02-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
CA2311742C (en) * 1997-11-28 2009-06-16 Sumitomo Pharmaceuticals Co., Ltd. 6-amino-9-benzyl-8-hydroxypurine derivatives
PT1049689E (pt) 1998-01-19 2002-09-30 Pfizer Compostos de 4-(2-ceto-1-benzimidazolinil)piperidina como agonistas do receptor orl1
CN1166665C (zh) * 1998-03-19 2004-09-15 日本农药株式会社 芳基哌啶衍生物及其用途
WO1999051608A1 (en) 1998-04-03 1999-10-14 Du Pont Pharmaceuticals Company THIAZOLO[4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
US5988695A (en) * 1998-08-26 1999-11-23 S&B Technical Products, Inc. Pipe gasket with embedded ring
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
DE69920757T2 (de) 1998-12-28 2005-12-15 4 AZA Bioscience N.V. Immunosuppressive wirkungen von pteridinderivaten
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
WO2000045800A2 (en) 1999-02-02 2000-08-10 K.U. Leuven Research & Development Immunosurpressive effects of pteridine derivatives
US6248755B1 (en) * 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6142484A (en) * 1999-04-15 2000-11-07 Vassallo Research & Development Corporation Composite multi-pressure gasket
US6930101B1 (en) * 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
AU5600100A (en) * 1999-06-11 2001-01-02 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity
US6340681B1 (en) 1999-07-16 2002-01-22 Pfizer Inc 2-benzimidazolylamine compounds as ORL-1-receptor agonists
BR0013952A (pt) 1999-09-15 2002-05-14 Warner Lambert Co Pteridinonas como inibidores de cinase
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
AR025884A1 (es) 1999-10-01 2002-12-18 Takeda Pharmaceutical Compuestos de amina ciclica, su produccion y su uso
ES2249237T3 (es) 2000-01-05 2006-04-01 Pfizer Inc. Compuestos de bencimidazol como antagonistas del receptor orl1.
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
JP2003522191A (ja) 2000-02-11 2003-07-22 アストラゼネカ・アクチエボラーグ ケモカイン受容体活性のモジュレーターとしてのピリミジン化合物およびそれらの使用
GB2359081A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359079A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
AU4274401A (en) * 2000-03-24 2001-10-03 Meiji Seika Kaisha Diphenylalkylamine derivatives useful as opioid delta receptor agonists
JP2003535078A (ja) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ 血管損傷活性のあるインドール誘導体
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
SE0003828D0 (sv) * 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
SE0004110L (sv) * 2000-11-10 2002-05-11 Forsheda Ab Tätningsring
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
GB0221828D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221829D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
JP2007507494A (ja) 2003-10-07 2007-03-29 アストラゼネカ・アクチエボラーグ ケモカイン受容体アンタゴニストとりわけＣＸ３ＣＲ１として有用な新規な２−置換４−アミノ−チアゾロ［４，５−ｄ］ピリミジン
GB0328243D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Methods
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
US20090239882A1 (en) 2004-12-17 2009-09-24 Astrazeneca Ab Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity

Also Published As

Publication number Publication date
JP4824889B2 (ja) 2011-11-30
PL365778A1 (en) 2005-01-10
NO20021448L (no) 2002-05-22
JP2003511384A (ja) 2003-03-25
UA73521C2 (en) 2005-08-15
CN1210279C (zh) 2005-07-13
CA2385269A1 (en) 2001-04-12
BR0014334A (pt) 2002-06-11
EP1348709A3 (en) 2003-11-19
NZ517880A (en) 2003-09-26
NO327706B1 (no) 2009-09-14
US20090281123A1 (en) 2009-11-12
DE60037836D1 (de) 2008-03-06
US20040224961A1 (en) 2004-11-11
DE60007768T2 (de) 2004-12-02
KR100765051B1 (ko) 2007-10-09
CZ20021113A3 (cs) 2002-06-12
ES2298451T3 (es) 2008-05-16
AU7304900A (en) 2001-05-10
DE60007768D1 (de) 2004-02-19
US6790850B1 (en) 2004-09-14
DK1222195T3 (da) 2004-04-19
NO20021448D0 (no) 2002-03-22
TWI260324B (en) 2006-08-21
HK1052009A1 (en) 2003-08-29
ES2213043T3 (es) 2004-08-16
WO2001025242A1 (en) 2001-04-12
DE60037836T2 (de) 2009-01-15
HUP0204246A3 (en) 2006-01-30
EP1222195A1 (en) 2002-07-17
EP1348709A2 (en) 2003-10-01
IS6306A (is) 2002-03-18
ZA200202380B (en) 2003-10-29
US8143261B2 (en) 2012-03-27
KR20020032635A (ko) 2002-05-03
MXPA02003263A (es) 2002-09-30
IL148910A (en) 2006-10-31
EP1222195B1 (en) 2004-01-14
EE200200174A (et) 2003-04-15
HUP0204246A2 (hu) 2003-04-28
PT1222195E (pt) 2004-05-31
EP1348709B1 (en) 2008-01-16
CN1402730A (zh) 2003-03-12
ATE257838T1 (de) 2004-01-15
ATE384068T1 (de) 2008-02-15
AU777872B2 (en) 2004-11-04
EE05037B1 (et) 2008-06-16
IS2229B (is) 2007-04-15
CA2385269C (en) 2010-08-17
IL148910A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
SE9903544D0 (sv) Novel compounds
SE9902987D0 (sv) Novel compounds
ATE248837T1 (de) Chinuclidin-acrylamide
TR200302214T4 (tr) Psoriasis tedavisi için kullanilan pteridine bileşkenleri
SE9904508D0 (sv) New compounds
ATE361288T1 (de) N-(3,-dimethylindolin-6-yl)ä2-ä(4-
ATE361287T1 (de) Neue indol-2-on derivate
SE0400043D0 (sv) New compounds
ATE233754T1 (de) Diphenyl-piperidin derivate
SE0101322D0 (sv) Novel compounds
PT992509E (pt) Novos derivados macrolidos
SE9804212D0 (sv) Compounds
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
SE0102057D0 (sv) New Salts I
SE0102058D0 (sv) New Salts II
BR9902049A (pt) Derivados 9a,11b-desidro de 9-oxima-3-ceto-6-o-metileritromicina.
MY135855A (en) &#34;pyrrolopyrimidinone derivatives, process of preparation and use&#34;